SAB Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SABS research report →
About the company
SAB Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
- CEO
- Samuel J. Reich
- IPO
- 2021
- Employees
- 86
- HQ
- Miami Beach, FL, US
Price Chart
- Market Cap
- $37.47M
- P/E
- 9.12
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- 7.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.29%
- ROIC
- -24.29%
- Revenue
- $0 · -100.00%
- Net Income
- $13.27M · 138.92%
- EPS
- $0.22 · 105.98%
- Op Income
- $-48,953,363
- FCF YoY
- -32.00%
- 52W High
- $6.60
- 52W Low
- $1.75
- 50D MA
- $3.69
- 200D MA
- $3.59
- Beta
- 0.53
- Avg Volume
- 850.84K
Get TickerSpark's AI analysis on SABS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Kropotova Alexandra | other | 988 |
| Mar 24, 26 | Kropotova Alexandra | other | 988 |
| Feb 3, 26 | Sullivan Eddie Joe | other | 3,000,000 |
| Feb 3, 26 | Reich Samuel J | other | 4,800,000 |
| Feb 3, 26 | Bausch Christoph Lawrence | other | 1,800,000 |
| Feb 3, 26 | Kropotova Alexandra | other | 2,400,000 |
| Feb 3, 26 | To Lucy | other | 2,400,000 |
| Jan 5, 26 | Jain Rita | other | 240,000 |
| Jan 5, 26 | ZACCARDELLI DAVID | other | 240,000 |
| Jan 5, 26 | Jain Rita | other | 0 |
Our SABS coverage
Recent articles, reports, and earnings notes.
No research on SABS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SABS report →Similar companies
Peers in the same neighborhood.